Obstructive sleep apnoea in acute coronary syndrome
We carefully read the results of the ISAACC study 1 and the excellent accompanying Comment. 2 In the Article, and to a greater extent in the Comment, the limitations of the ISAACC study are well articulated and highlighted. However, some key additional points need attention.
Firstly, in our opinion, the most salient finding of the trial has not been sufficiently stressed. The presence of moderate-to-severe obstructive sleep apnoea (OSA) does not impose an additional cardiovascular risk; hence, a beneficial effect of continuous positive airway pressure (CPAP) treatment should not be expected. In fact, several studies have observed a controversial influence of OSA on coronary outcomes. 3 Thus, the key question would be whether coronary heart disease is an adequate outcome to assess the beneficial effect of CPAP.
Secondly, the so-called composite outcome has frequently been used to increase statistical power of studies. However, several authors have warned of the risks associated with such an approach, particularly when the relative weight of selected outcomes is very different, 4 which is the case in the ISAACC 2 and SAVE studies. 5 For example, it seems unreasonable to assign the same weight to a transient ischaemic attack episode and stroke death, or to stable angina and myocardial infarction death.
Thirdly, several large observational studies and some randomised controlled trials (including the SAVE study) reported that the effect of CPAP on cerebrovascular events differs greatly from its effect on coronary events in intention-to-treat and especially in per protocol analyses. 3 In the ISAACC study, the small number of cerebrovascular events observed precluded any statistical significance, but presented the highest odds ratio values for the protective effect of CPAP out of all studies reported so far. Therefore, including cerebrovascular and coronary events in the same composite outcome could have masked the effect of CPAP, leading to erroneous conclusions. It is probable that regulation of coronary vessels differs from that of cerebral vessels in the context of OSA, and might account for discrepant effects of CPAP. 6 Therefore, it would be premature to take the findings of the ISAACC and SAVE studies at face value, and assume that they represent definitive answers to the question on the effect of CPAP on cardiovascular events. In this sense, it is crucial to begin a study by properly choosing the study outcomes. Given the information available, perhaps the fatal and non-fatal cerebrovascular events should be the first separate non-composite outcomes to be explored. Large-scale studies are realistically achievable according to some multinational studies on the primary prevention of stroke. 7 Additionally, education efforts aimed at improving CPAP adherence would also be desirable. Therefore, rather than concluding that CPAP is not effective for cardiovascular protection, we propose that future studies can benefit from the lessons learned from these pioneering studies, and should focus more explicitly on well-defined targeted outcomes.
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